Simcere Of China Says New Use Of Biotech Endu Favorable
This article was originally published in PharmAsia News
Executive Summary
China's Simcere Pharmaceuticals said its Endu, an endostatin biotech drug already approved for treating lung cancer, has demonstrated in interim results it is safe when used with platinum-containing chemotherapy. China's State FDA sought a re-evaluation of the drug before it would grant the new indication. Simcere said the new trial, expected to be completed in 2010, appears to show the drug is well-tolerated with chemotherapy. (Click here for more
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.